# 2026-10190: FDA Tweaks Patent Delay Petitions for Drugs

2026-10190, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-21, effective Submit written comments (including recommendations) on the collection of information by June 22, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-10190
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-10190
- Title: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 29969
- Published: 2026-05-21
- Effective: Submit written comments (including recommendations) on the collection of information by June 22, 2026.
- Comments close: 2026-06-22
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Tweaks Patent Delay Petitions for Drugs

## Summary

The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.

## Abstract

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

## Effects PRIA read

- Paperwork Rules for Patent Extensions: cost, low. If you are a patent holder for a new drug, biologic, medical device, animal drug, food additive, or color additive, FDA is continuing the information-collection requirements (OMB control number 0910-0233) for petitions under 21 CFR part 60. The agency submitted this paperwork collection to OMB for…
- Estimated Annual Time Burden: cost, medium. FDA estimates annual respondent burden of 560 hours total: five revision requests of regulatory review period determinations at 100 hours each (500 hours), one due diligence petition at 50 hours, and one due diligence hearing request at 10 hours. FDA estimates no capital or operating costs and base…
- No Change to 'Due Diligence' Definition: cost, low. FDA stated it believes the existing definition of "due diligence" in 21 CFR 60.36(a) is adequate and will not revise that definition in this submission. Petitioners should plan under the current definition, which FDA quotes as the degree of attention, continuous directed effort, and timeliness reas…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-10190 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/21/2026-10190/agency-information-collection-activities-submission-for-office-of-management-and-budget-review)
- [2026-10190 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-21/pdf/2026-10190.pdf)

## Related
- [Previous: 2026-10189, Agency Information Collection Activities; Submission for Office of Management a…](https://policyrisk.com/federal-register/2026-10189)
- [Next: 2026-10191, Agency Information Collection Activities; Proposed Information Collection Reque…](https://policyrisk.com/federal-register/2026-10191)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-10190 (as of 2026-06-08).
